Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 2/20 | 0.60 |
| ▸ | MAOB | P27338 | 11/20 | 0.58 |
| ▸ | MAOA | P21397 | 3/20 | 0.58 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.52 |
| ▸ | PPARA | Q07869 | 1/20 | 0.48 |
| ▸ | GSK3B | P49841 | 1/20 | 0.47 |
| ▸ | BACE1 | P56817 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6665583 | 0.87 | MAOB (0.55) | NR4A2MAOBBACE1 | |
| SCHEMBL5875478 | 0.87 | MAOB (0.58) | NR4A2MAOBMAOAPARP10 | |
| SCHEMBL27634590 | 0.84 | NR4A2 (0.59) | NR4A2MAOBMAOAPARP10PPARA | |
| SCHEMBL6306323 | 0.83 | NR4A2 (0.70) | NR4A2MAOBMAOAPARP10PPARA | |
| SCHEMBL4424360 | 0.83 | MAOB (0.80) | NR4A2MAOBMAOAPARP10PPARA | |
| SCHEMBL4338716 | 0.83 | MAOB (0.60) | NR4A2MAOBMAOAPARP10 | |
| SCHEMBL810582 | 0.81 | MAOB (0.55) | NR4A2MAOBMAOAPARP10 | |
| SCHEMBL30152219 | 0.81 | MAOB (0.57) | NR4A2MAOBMAOAPARP10 | |
| SCHEMBL3363943 | 0.81 | MAOB (0.57) | NR4A2MAOBMAOAPARP10 | |
| SCHEMBL5875467 | 0.80 | NR4A2 (0.65) | NR4A2MAOBMAOAPARP10PPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100418954-C | 3h-quinazolin-4-one derivatives | HOFFMANN LA ROCHE (CH) | 2008-09-17 | — | — | CN | disclosed |
| EP-1572666-B1 | 3H-QUINAZOLIN-4-ONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2006-08-09 | — | — | EP | disclosed |
| US-7087612-B2 | Amine oxidase inhibitor; therapy for Alzheimer's diseases, Parkinson's disease | HOFFMANN-LA ROCHE INC. (US) | 2006-08-08 | — | — | US | disclosed |
| CN-1720237-A | 3h-quinazolin-4-one derivatives | HOFFMANN LA ROCHE (CH) | 2006-01-11 | — | — | CN | disclosed |
| EP-1572666-A1 | 3H-QUINAZOLIN-4-ONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-09-14 | — | — | EP | disclosed |
| US-20040142951-A1 | 3H-quinazolin-4-one derivatives as MAO-B inhibitors | F. HOFFMANN-LA ROCHE AG (CH) | 2004-07-22 | — | — | US | disclosed |
| WO-2004054985-A1 | 3H-QUINAZOLIN-4-ONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142951-A1 | 3H-quinazolin-4-one derivatives as MAO-B inhibitors | MAOB, MAOA, COMT | NR4A2 2124/4885MAOB 1/4885MAOA 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.